ArrowMark Colorado Holdings’s Dianthus Therapeutics DNTH Stock Holding History

ArrowMark Colorado Holdings’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.03M	Hold	20,788	–	–	0.08%	224
2026 Q1	$1.74M	Hold	20,788	–	–	0.05%	226
2025 Q4	$857K	Hold	20,788	–	–	0.02%	267
2025 Q3	$818K	Hold	20,788	–	–	0.02%	257
2025 Q2	$387K	Hold	20,788	–	–	0.01%	282
2025 Q1	$377K	Hold	20,788	–	–	0.01%	278
2024 Q4	$453K	Hold	20,788	–	–	0.01%	284
2024 Q3	$569K	Hold	20,788	–	–	0.01%	271
2024 Q2	$538K	Hold	20,788	–	–	0.01%	285
2024 Q1	$624K	Hold	20,788	–	–	0.01%	283
2023 Q4	$216K	Hold	20,788	–	–	﹤0.01%	294
2023 Q3	$284K	Buy	+20,788	New	+$262K	﹤0.01%	288

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

ArrowMark Colorado Holdings's DNTH Position: Q2 2026 in Review

ArrowMark Colorado Holdings held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 20,788 shares worth $2.03M. The position accounts for 0.08% of the portfolio, ranked #224.

ArrowMark Colorado Holdings first reported a position in DNTH in Q3 2023 and has held it in 12 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

ArrowMark Colorado Holdings held 20,788 shares of Dianthus Therapeutics worth $2.03M as of Q2 2026.
ArrowMark Colorado Holdings left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 0.08% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #224 holding.
ArrowMark Colorado Holdings first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 12 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.